A biomarker analysis using available primary tumor from 227 (31%) patientsfrom this study and a Foundation Medicine 182 cancer-mutation panel foundPIK3CA was the most frequently mutated gene among the cases analyzed (48%).However, it was not found to be predictive, with similar treatment benefit derived fromthe everolimus plus exemestane therapy among PIK3CA mutated and wild-typebreast cancer patients [76]. Here, PIK3CA is linked to cancer.